Edwards Lifesciences' Q4 revenue beats estimates, partly helped by TMTT sales

Edwards Lifesciences

10/02/2026 21:23

Overview

Heart valve maker's Q4 sales grew 13.3%, beating analyst expectations

Adjusted EPS for Q4 missed analyst expectations

Company's TMTT sales grew over 40% to $156 mln, driven by repair and replacement therapies

Outlook

Edwards Lifesciences projects 2026 sales growth of 8-10%

Company expects 2026 adjusted EPS between $2.90 and $3.05

Edwards Lifesciences forecasts TMTT revenue of $740-780 mln in 2026

Result Drivers

TAVR SALES GROWTH - Q4 TAVR sales increased 12% to $1.16 bln, driven by procedural growth and stable pricing, supported by long-term trial evidence

TMTT SALES EXPANSION - Q4 TMTT sales grew over 40% to $156 mln, driven by adoption of PASCAL and EVOQUE, and introduction of SAPIEN M3

EUROPEAN GUIDELINES IMPACT - New European guidelines reshaped clinical discussions, reinforcing TAVR's role for broader patient population

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$1.57 bln
$1.55 bln (27 Analysts)
Q4 Adjusted EPS
Miss
$0.58
$0.62 (26 Analysts)
Q4 EPS
$0.16


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Edwards Lifesciences Corp is $98.00, about 27.6% above its February 9 closing price of $76.80

Press Release: ID:nBw9nr156a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)